Out-of-stock situation regarding Strangvac in Sweden resolved
Stockholm, October 21, 2024 – Intervacc AB (publ) announces that the shortage situation for the equine strangles vaccine Strangvac in Sweden has been resolved and the vaccine is again in stock for distribution and sales. As previously announced, the shortage situation arose on October 1, 2024, and was expected to last until mid-October.
The company applied through a special procedure, Special Batch Release (SBR), to allow for the newly manufactured batches available for sale. The company can today announce that after receiving approval for SBR in Sweden, Strangvac is available for immediate delivery in Sweden.
The procedure and processes, including Special Batch Release, vary in different countries, and the time to make Strangvac available again in other markets will vary.
“We are very pleased that the Swedish Medical Products Agency has acted diligently, which has made it possible for Strangvac to be available again for immediate delivery.” commented CEO Jonas Sohlman.
For more information please contact:
Jonas Sohlman, CEO
Phone: +46 (0)8 120 10 600
E-mail: [email protected]
The information was submitted for publication, through the agency of the contact person set out above on October 21, 2024, 4.10 p.m. CET.
About Strangvac
Strangvac, a vaccine against equine strangles, is approved for sale and marketing in the EU, as well as in the United Kingdom, Iceland, Norway, and Liechtenstein. It has been launched in Sweden, Denmark, the United Kingdom, France, Germany, Belgium, the Netherlands, Austria, Ireland, Poland, and Italy.
About Intervacc
Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company's vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Sciences where the foundation was laid for the Company´s research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017.
Contact information for Certified Adviser
Eminova Fondkommission AB
E-mail: [email protected], Phone: +46 (0)8 – 684 211 10
